Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. |
|
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
GRASSO MARC | Chief Financial Officer | Dec 02 '24 | Sale | 2.52 | 16,489 | 41,542 | 330,651 | Dec 03 05:40 PM | Rosenthal Arnon | Chief Executive Officer | Dec 02 '24 | Sale | 2.52 | 52,172 | 131,442 | 2,507,074 | Dec 03 05:40 PM | Kenkare-Mitra Sara | President and Head of R&D | Dec 02 '24 | Sale | 2.52 | 26,500 | 66,764 | 565,215 | Dec 03 05:40 PM | Romano Gary | Chief Medical Officer | Dec 02 '24 | Sale | 2.52 | 14,892 | 37,519 | 349,283 | Dec 03 05:40 PM | Gary Romano | Officer | Dec 02 '24 | Proposed Sale | 2.59 | 14,306 | 37,053 | | Nov 29 03:00 PM | Sara Kenkare-Mitra | Officer | Dec 02 '24 | Proposed Sale | 2.59 | 25,465 | 65,954 | | Nov 29 03:00 PM | Marc Grasso | Officer | Dec 02 '24 | Proposed Sale | 2.59 | 15,842 | 41,031 | | Nov 29 03:00 PM | Arnon Rosenthal | Officer | Dec 02 '24 | Proposed Sale | 2.59 | 50,142 | 129,868 | | Nov 29 03:00 PM | GRASSO MARC | Chief Financial Officer | Sep 03 '24 | Sale | 4.88 | 7,297 | 35,620 | 130,740 | Sep 04 04:44 PM | Rosenthal Arnon | Chief Executive Officer | Sep 03 '24 | Sale | 4.88 | 26,499 | 129,387 | 1,948,746 | Sep 04 04:15 PM | Kenkare-Mitra Sara | President and Head of R&D | Sep 03 '24 | Sale | 4.88 | 13,926 | 67,981 | 291,715 | Sep 04 04:15 PM | Romano Gary | Chief Medical Officer | Sep 03 '24 | Sale | 4.88 | 8,478 | 41,385 | 179,795 | Sep 04 04:15 PM | Arnon Rosenthal | Officer | Sep 03 '24 | Proposed Sale | 5.28 | 24,359 | 128,616 | | Aug 30 05:18 PM | Sara Kenkare-Mitra | Officer | Sep 03 '24 | Proposed Sale | 5.28 | 12,796 | 67,563 | | Aug 30 05:18 PM | Marc Grasso | Officer | Sep 03 '24 | Proposed Sale | 5.28 | 6,703 | 35,392 | | Aug 30 05:18 PM | Gary Romano | Officer | Sep 03 '24 | Proposed Sale | 5.28 | 7,788 | 41,121 | | Aug 30 05:18 PM | SCHELLER RICHARD H | Director | Aug 22 '24 | Sale | 5.16 | 44,250 | 228,388 | 35,000 | Aug 23 04:05 PM | SCHELLER RICHARD H | Director | Aug 22 '24 | Proposed Sale | 4.75 | 44,250 | 210,188 | | Aug 22 05:31 PM | Hammond Paula | Director | Aug 12 '24 | Sale | 5.06 | 10,500 | 53,179 | 60,209 | Aug 13 07:55 PM | Yaffe Kristine | Director | Aug 12 '24 | Sale | 5.06 | 5,000 | 25,309 | 67,709 | Aug 13 07:55 PM | PAULA HAMMOND | Director | Aug 12 '24 | Proposed Sale | 5.06 | 10,500 | 53,179 | | Aug 12 04:34 PM | Romano Gary | Chief Medical Officer | Jun 03 '24 | Sale | 4.80 | 8,040 | 38,582 | 188,273 | Jun 04 06:05 PM | Kenkare-Mitra Sara | President and Head of R&D | Jun 03 '24 | Sale | 4.80 | 13,206 | 63,373 | 305,641 | Jun 04 06:05 PM | Rosenthal Arnon | Chief Executive Officer | Jun 03 '24 | Sale | 4.80 | 25,135 | 120,618 | 1,975,245 | Jun 04 06:05 PM | GRASSO MARC | Chief Financial Officer | Jun 03 '24 | Sale | 4.80 | 6,920 | 33,208 | 138,037 | Jun 04 06:05 PM | GRASSO MARC | Chief Financial Officer | Mar 04 '24 | Sale | 6.92 | 5,716 | 39,562 | 144,957 | Mar 05 06:00 PM | Rosenthal Arnon | Chief Executive Officer | Mar 04 '24 | Sale | 6.92 | 18,837 | 130,386 | 2,000,380 | Mar 05 06:00 PM | Romano Gary | Chief Medical Officer | Mar 04 '24 | Sale | 6.92 | 6,001 | 41,554 | 196,313 | Mar 05 06:00 PM | Kenkare-Mitra Sara | President and Head of R&D | Mar 04 '24 | Sale | 6.92 | 10,169 | 70,387 | 318,847 | Mar 05 06:00 PM |
|